Emily Fairbairn
Emily Fairbairn's purchase track record
How the stock did after each of Emily Fairbairn's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/14/2023 | MOVE | $251K | -34.1% | -54.0% | +16.7% |
| 6/13/2023 | MOVE | $250K | +8.0% | -30.6% | +6.3% |
| 8/16/2022 | INAB | $1.50M | -15.3% | +1.9% | -3.9% |
| 3/31/2022 | MOVE | $22K | -11.8% | -0.4% | -19.6% |
| 11/18/2021 | MOVE | $39K | -28.3% | -49.6% | -17.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
IN8bio Reports Inducement Grant Under Nasdaq Rule. IN8bio disclosed an inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate governance procedure used to attract or retain key employees. The stock is currently trading near its 52-week high, with technical indicators showing recent support rejection.
Transaction History
| MOVE | ▼ Sell | Other | 1,205,282 | $0 | 7/7/2026 | View on chart |
| MOVE | ▲ Buy | Grant | 135,800 | $0 | 7/1/2026 | View on chart |
| INAB | ▼ Sell | Gift | 724,637 | $0 | 5/27/2026 | View on chart |
| MOVE | ▼ Sell | Other | 9,231 | $0 | 3/31/2026 | View on chart |
| MOVE | ▲ Buy | Option Exercise | 55,250 | $69K | 3/16/2026 | View on chart |
| MOVE | ▲ Buy | Grant | 4,470 | $0 | 1/9/2026 | View on chart |
| MOVE | ▲ Buy | Grant | 5,959 | $0 | 1/9/2026 | View on chart |
| INAB | ▲ Buy | Grant | 724,637 | $1000K | 12/22/2025 | View on chart |
| MOVE | ▼ Sell | Other | 12,442 | $0 | 11/3/2025 | View on chart |
| MOVE | ▲ Buy | Grant | 31,028 | $0 | 10/3/2025 | View on chart |
| MOVE | ▲ Buy | Grant | 27,985 | $0 | 7/3/2025 | View on chart |
| MOVE | ▲ Buy | Grant | 65,407 | $0 | 5/9/2025 | View on chart |
| MOVE | ▲ Buy | Open Market | 4,690,000 | — | 4/2/2024 | View on chart |
| MOVE | ▲ Buy | Open Market | 295,000 | $251K | 11/14/2023 | View on chart |
| INAB | ▼ Sell | Other | 4,111,958 | $0 | 7/28/2023 | View on chart |
| MOVE | ▲ Buy | Open Market | 250,000 | $250K | 6/13/2023 | View on chart |
| MOVE | ▲ Buy | Open Market | 178,571 | — | 1/27/2023 | View on chart |
| INAB | ▲ Buy | Open Market | 789,473 | $1.5M | 8/16/2022 | View on chart |
| MOVE | ▲ Buy | Open Market | 3,011 | $9K | 4/1/2022 | View on chart |
| MOVE | ▲ Buy | Open Market | 5,000 | $14K | 3/31/2022 | View on chart |
| MOVE | ▲ Buy | Open Market | 5,000 | $19K | 11/23/2021 | View on chart |
| MOVE | ▲ Buy | Open Market | 1,000 | $4K | 11/18/2021 | View on chart |
| MOVE | ▲ Buy | Open Market | 4,000 | $16K | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Corvex files prospectus for share resale and seeks Whitbread board seat
Corvex has filed a prospectus to register the resale of up to 4,258,068 common shares on behalf of selling stockholders. At the same time, an activist linked to Corvex is pursuing a board seat at Whitbread, citing concerns over the company's strategy. The share resale filing could increase the number of shares available in the market, while the activist effort highlights the firm's involvement in governance matters beyond its own operations.
Corvex files prospectus for share resale and seeks Whitbread board seat. Corvex has filed a prospectus to register the resale of up to 4,258,068 common shares on behalf of selling stockholders. At the same time, an activist linked to Corvex is pursuing a board seat at Whitbread, citing concerns over the company's strategy. The share resale filing could increase the number of shares available in the market, while the activist effort highlights the firm's involvement in governance matters beyond its own operations.